CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
Alpha-Tocopherol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03948737
NCT03948737N/ACompleted

The Effect of Alpha-tocopherol in Hemolysis and Oxidative Stress Marker on the Red Cell

Indonesia University·interventional·Posted May 14, 2019·Updated May 14, 2019

In Brief

A clinical study evaluating Alpha-Tocopherol and Placebo oral tablet for Beta Thalassemia Major Anemia and 2 related conditions. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The accumulation of unpaired α-globin chains in β-thalassemia major patients may clinically create ineffective erythropoiesis, hemolysis, and chronic anemia. Multiple blood transfusions and iron overload cause cellular oxidative damage. However, α-tocopherol, an antioxidant, has been known as a potent scavenger of lipid radicals in the red cell membrane of β-thalassemia major patient. By this randomized controlled trial, the investigators would like to evaluate the effects of α-tocopherol in hemolysis and oxidative stress on the red cell membrane of β-thalassemia major.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIndonesia
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 14, 2019
Enrollment StartDec 30, 2016
Primary CompletionJul 30, 2017
Study CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.1 years ago

Interventions

Alpha-Tocopheroldrug

all of the subjects in the alpha-tocopherol group received alpha-tocopherol orally, doses adjusted by age for 4 weeks of treatment.

Placebo oral tabletdrug